Australia's largest stock trading and investment forum Australia's #1 stock forum

CPH

Click for more information

0.00%

0.9¢ creso pharma limited

what it says and actually what happens are 2 different things im...

First 68 Last

Share
Profile

Follow
Carmenbella

129 Posts.

22/03/17

12:30

Post #: 23540154
Share

Originally posted by SteveGolu ↑

Carmen Bella, belisima, simpatica, cara mia DYOR or read this

Sales of CPH’s products in Brazil will target the privately insured middle class population of 60 million people. That is potentially a large addressable market $US800 million.

SmlFry said:

Creso Pharma Limited (ASX:CPH, the “Company”) is pleased to announce that it has signed a binding Letter Of Intent (LOI) with Brazil-based Sin Solution for the marketing, sale and distribution of Creso products in Brazil. Latin America is a key market for Creso and the agreement provides the Company with a strategic foothold from which it can expand the launch of its cannabinoid-derived nutraceutical products into other countries in the region. The sale of Creso’s products in Brazil will target the privately insured middle class population of 60 million people, giving it a potential market of more than $US800 million. Sin Solution is a Brazil-based company that specialises in the market-access, sale and distribution services of health care products in Brazil and across Latin America. It has access to more than 350,000 health professionals and over 200, 000 direct patient contacts in the region. Sin Solution has an extensive commercial network, working with a number of high-profile commercial partners across the food manufacturing and pharmaceutical industries including global medical device, pharmaceutical and consumer goods manufacturer Johnson & Johnson, as well as GSK and Takeda.

It also works with a number of key marketing and distribution partners, including:

• Medicinal prescription and over-the-counter (OTC) pharmaceuticals and distribution company, Ache Do Brasil, which has more than 65,000 points of sales in Brazil. Ache Do Brasil promotes 316 brands and had 2015 net revenues of R$2.3 billion (A$1 billion).
• Hypermarcas, the number one OTC pharmaceuticals company in Brazil with 15% market share and sales totalling R$1 billion (A$420 million) in 2015.
• Biolab, which is among the top-10 biggest pharmaceutical companies in Brazil, with a field force of 1050 people.

Biolab had sales of US$370 million in 2015, covering 250,000 medical professionals in Brazil and a market share of 2.13%. Through the LOI, Sin Solution will act as a commercial partner for the commercialisation in Brazil of Creso’s various Swiss Vitamin premium nutraceutical products as well as its cannabinoid-derived nutraceutical products. The Swiss Vitamin premium nutraceutical products are based on INNutri’s unique delivery technology with buccal absorption and high bioavailability of premium vitamin mixes supporting different health applications. They are targeted to the active middle-class working population. Introducing the Swiss Vitamin nutraceutical products to the market will prepare the groundwork for the successful launch of Creso’s cannabinoid-derived nutraceutical product using the same innovative buccal delivery technology that specifically targets anxiety and stress. Creso will now proceed to register the premium Swiss Vitamin products in Brazil, followed by a launch in 2H2018. The registration of the cannabinoid-derived nutraceutical product will follow the product launch in the Swiss market. Creso expects first sales of its products in Brazil to occur in 2H2018. This will be quickly followed by sales into other Central/Latin American markets with the related partners. “This agreement gives Creso entry into Latin America via a strategic partner in the continent’s largest economy, Brazil. Working with Sin Solution gives us access to further key commercial partners in the region and allows us to tap into a vast and fast-growing market, supporting the long-term growth of our business,” said Creso Pharma Group CEO and Co-Founder, Dr. Miriam Halperin Wernli.

Expand

what it says and actually what happens are 2 different things im just telling you middle class in brazil a few and far between.Goodluck to all holders

CPH Price at posting: 82.5¢ Sentiment: None Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Microcap Wrap: 5 explorers with news out today

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

RCE

Recce's R327 found effective against E.coli during clinical trial

There are more pages in this discussion • 79 more messages in this thread...

First 68 Last

Add CPH (ASX) to my watchlist

SPONSORED BY